What is NeuroOne Medical Technologies Days Payable?
NeuroOne Medical TechnologiesNMTC -2.89%39 Days Payable is 61.41 as of Mar. 2026, which is 69% below its 10-year median of 196.90. GuruFocus rates NMTC with a GF Score™ of 39/100 and a GF Value™ of $6.58 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 795 Medical Devices & Instruments companies, NeuroOne Medical Technologies ranks worse than 54.34% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NMTC vs RDGL, TANAF, MODD: Days Payable Comparison
For the Medical Devices subindustry, NeuroOne Medical Technologies's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NeuroOne Medical Technologies Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NeuroOne Medical Technologies's Days Payable distribution charts can be found below:
* The bar in red indicates where NeuroOne Medical Technologies's Days Payable falls into.
NeuroOne Medical Technologies Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NeuroOne Medical Technologies (NMTC) has a Days Payable of 61.41 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on NeuroOne Medical Technologies and its competitors. This is 69% below median its historical median of 196.90. Over the past decade, NeuroOne Medical Technologies' Days Payable has ranged from 63.97 to 1,098.77. According to the industry distribution chart, NeuroOne Medical Technologies ranks #432 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 54.3%.
Is NeuroOne Medical Technologies' Days Payable too high?
NeuroOne Medical Technologies' current Days Payable of 61.41 is 69% below median its 10-year median of 196.90. Over the past 10 years, this metric has ranged from a low of 63.97 to a high of 1,098.77. The Medical Devices & Instruments industry median Days Payable is 68.07. NeuroOne Medical Technologies' value of 61.41 is 9.8% below this industry median. Based on the distribution chart, NeuroOne Medical Technologies ranks #432 out of 795 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, NeuroOne Medical Technologies has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does NeuroOne Medical Technologies' Days Payable compare to RDGL and TANAF?
According to the Medical Devices & Instruments industry distribution chart, NeuroOne Medical Technologies ranks #432 out of 795 companies for Days Payable. This places NeuroOne Medical Technologies in the lower half of its industry. The industry median Days Payable is 68.07. NeuroOne Medical Technologies' value of 61.41 is 9.8% below this benchmark. Historically, NeuroOne Medical Technologies' own Days Payable has ranged from 63.97 to 1,098.77 over the past decade. While the company's 10-year median is 196.90 vs. the industry median of 68.07, NeuroOne Medical Technologies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.07, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NeuroOne Medical Technologies's current Days Payable of 61.41 is 9.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on NeuroOne Medical Technologies and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NeuroOne Medical Technologies's current Days Payable is 61.41, which is 69% below median its own 10-year median of 196.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuroOne Medical Technologies stock overvalued right now?
Based on GuruFocus' analysis, NeuroOne Medical Technologies (NMTC) is currently considered Possible Value Trap. The stock's GF Value™ is $6.58, compared to a current price of $3.22 — trading 51% below its estimated fair value. The current Days Payable is 61.41, which is 69% below median its 10-year median of 196.90 and 9.8% below the Medical Devices & Instruments industry median of 68.07. NeuroOne Medical Technologies' overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For NeuroOne Medical Technologies (NMTC), the current Days Payable is 61.41 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NeuroOne Medical Technologies (NMTC) Overvalued in 2026?
Based on GuruFocus' analysis, NeuroOne Medical Technologies stock appears to be undervalued.
The current stock price of $3.22 is trading 51% below its estimated GF Value™ of $6.58.
GuruFocus considers NeuroOne Medical Technologies to be Possible Value Trap.
Key valuation signals for NMTC:
Days Payable: 61.41 (69% below median its 10-year median of 196.90)
GF Value™: $6.58 vs. price of $3.22 (51% below fair value)
Industry Position: 9.8% below the Medical Devices & Instruments median (#432 of 795)
No single metric tells the full story. See the NMTC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NeuroOne Medical Technologies Business Description
NeuroOne Medical Technologies Corp is focused on diagnostic, ablation, and deep brain stimulation technology for brain-related conditions such as epilepsy and Parkinson's disease; ablation and stimulation for pain management; and drug delivery with diagnostic and stimulation capabilities. It develops thin film electrode technology for various recording and therapeutic applications, crucial for diagnosing neurological disorders such as epilepsy, Parkinson's disease, dystonia, and essential tremors. The company operates in one segment, developing and commercializing products for neuromodulation, cEEG, and sEEG recording, monitoring, ablation, and brain stimulation, with revenue from Evo Cortical, Evo sEEG, and OneRF Ablation System.
39GF Score
Get the complete analysis for NMTC
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NMTC has been successfully added to your 
